Chemomab Therapeutics Ltd. (CMMB) shareholders
Close on Nov 17, 2026Market cap $11.80MP/E 1.1Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| HBM Healthcare Investments (Cayman) Ltd. | 80,971,680 | 12.50% | 13D (active) amendment | Sep 7, 2026 |
| Scipher Medicine Corp | 74,576,240 | 10.40% | 13D (active) | Nov 3, 2026 |
| Morgan Stanley Joint filing with Morgan Stanley & Co. LLC (7.50%) | 32,282,680 | 8.40% | 13G (passive) | Jun 30, 2025 |
| Touchstone Global Investments Pty Ltd | 377,814 | 5.20% | 13G (passive) | Aug 7, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CMMB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 95,311 | 0.02% | $154.40K | +31,129 | 0.00% |
| ADAR1 Capital Management, LLC | 80,000 | 0.01% | $129.60K | – | 0.01% |
| Kestra Private Wealth Services, LLC | 61,710 | 0.01% | $99.97K | – | 0.00% |
| Ikarian Capital, LLC | 51,793 | 0.01% | $83.90K | – | 0.01% |
| Rhumbline Advisers | 30,529 | 0.01% | $49.46K | +12,163 | 0.00% |
| XTX Topco Ltd | 15,987 | 0.00% | $25.90K | −2,642 | 0.00% |
| Philadelphia Investment Partners, LLC | 15,000 | 0.00% | $24.30K | +6,800 | 0.02% |
| Lido Advisors, LLC | 14,341 | 0.00% | $23.23K | New | 0.00% |
| Bnp Paribas Arbitrage, Snc | 6,805 | 0.00% | $11.02K | −1,620 | 0.00% |
| GAMMA Investing LLC | 4,740 | 0.00% | $7.68K | −2,839 | 0.00% |
| Morgan Stanley | 3,575 | 0.00% | $5.79K | −1,000 | 0.00% |
| SBI Securities Co., Ltd. | 34 | 0.00% | $55 | +6 | 0.00% |
| Caitong International Asset Management Co., Ltd | 8 | 0.00% | $13 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 0M | 0.1% | 1 / 4 | 4 / 3 | 0M | 0M |
| Q1 2026 | 15 | 0M | 0.1% | 4 / 6 | 3 / 3 | 0M | 0M |
| Q4 2025 | 14 | 0M | 0.1% | 6 / 4 | 3 / 2 | 0M | 0M |
| Q3 2025 | 10 | 0M | 0.1% | 1 / 2 | 6 / 5 | 0M | 1M |
| Q2 2025 | 14 | 1M | 0.2% | 2 / 5 | 3 / 5 | 0M | 0M |
| Q1 2025 | 17 | 1M | 0.2% | 1 / 8 | 3 / 0 | 0M | 0M |
| Q4 2024 | 16 | 1M | 0.2% | 5 / 1 | 6 / 4 | 0M | 0M |
| Q3 2024 | 15 | 1M | 0.2% | 5 / 4 | 2 / 22 | 1M | 1M |
| Q2 2024 | 33 | 2M | 0.3% | 3 / 12 | 7 / 7 | 0M | 0M |
| Q1 2024 | 37 | 2M | 0.3% | 5 / 6 | 11 / 3 | 0M | 0M |
| Q4 2023 | 35 | 2M | 0.3% | 8 / 6 | 10 / 3 | 0M | 0M |
| Q3 2023 | 30 | 2M | 0.3% | 4 / 7 | 9 / 10 | 0M | 1M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| George Adi Mor | Chief Executive Officer, Director | 68,809 | 0.01% | Jun 1, 2026 |
| Sigal Fatal | Chief Financial Officer | 12,500 | 0.00% | Apr 10, 2026 |
| John Lawler | Chief Development Officer | 10,148 | 0.00% | Apr 10, 2026 |
| Neil Harris Cohen | Director | 33,000 | 0.01% | Sep 1, 2026 |
| Gwen A. Melincoff | Director | – | – | Jun 3, 2026 |
| Alan Charles Moses | Director | – | – | Apr 10, 2026 |
| Nissim Darvish | Director | 300 | 0.00% | Apr 10, 2026 |
| Claude Nicaise | Director | – | – | Mar 31, 2026 |
| Jill M. Quigley | Director | – | – | Mar 31, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Neil Harris Cohen Director | Aug 28, 2026 | Sale | −1,000 | $2.80 | $2.80K | 33,000 |
| Neil Harris Cohen Director | Aug 27, 2026 | Sale | −1,304 | $2.85 | $3.72K | 34,000 |
| George Adi Mor Chief Executive Officer, Director | May 29, 2026 | Other | −18,750 | – | – | 18,750 |
| George Adi Mor Chief Executive Officer, Director | May 29, 2026 | Other | −31,712 | – | – | 31,712 |
| George Adi Mor Chief Executive Officer, Director | May 29, 2026 | Buy | −4,926 | $2.08 | $10.25K | 139,131 |
| George Adi Mor Chief Executive Officer, Director | May 29, 2026 | Buy | −4,878 | $2.05 | $10.00K | 134,205 |
| Israel BioFund GP Limited Partnership OrbiMed 10% owner | Jan 3, 2023 | Sale | −266,376 | $3.34 | $889.70K | 2,311,798 |
| Israel BioFund GP Limited Partnership OrbiMed 10% owner | Jan 3, 2023 | Sale | −70,524 | $4.51 | $318.06K | 2,241,274 |
| George Adi Mor Chief Scientific Officer, Director | Jan 3, 2023 | Sale(10b5-1 plan) | −7,700 | $5.03 | $38.73K | 317,075 |
| George Adi Mor Chief Scientific Officer, Director | Jan 3, 2023 | Sale(10b5-1 plan) | −6,100 | $5.03 | $30.68K | 251,147 |
| Neil Harris Cohen Director | Nov 16, 2022 | Sale | −2,409 | $2.00 | $4.82K | 10,000 |
| George Adi Mor Chief Scientific Officer, Director | Nov 16, 2022 | Sale | −257,248 | $2.08 | $535.08K | 257,247 |
| George Adi Mor Chief Scientific Officer, Director | Nov 16, 2022 | Sale | −324,775 | $2.08 | $675.53K | 324,775 |
| Joel Michael Maryles Director | May 24, 2022 | Buy | +33 | $2.76 | $91 | 1,433 |
| Joel Michael Maryles Director | May 24, 2022 | Buy | +400 | $2.89 | $1.16K | 1,400 |
| Neil Harris Cohen Director | May 18, 2022 | Buy | +2,000 | $3.19 | $6.38K | 12,409 |
| Joel Michael Maryles Director | Mar 18, 2022 | Buy | +500 | $4.32 | $2.16K | 500 |
| Joel Michael Maryles Director | Mar 18, 2022 | Buy | +500 | $4.36 | $2.18K | 1,000 |
| Donald Marvin Executive VP, CFO & COO | Mar 16, 2022 | Buy | +250 | $3.25 | $813 | 2,000 |
| Donald Marvin Executive VP, CFO & COO | Mar 16, 2022 | Buy | +250 | $3.30 | $825 | 1,750 |
| Donald Marvin Executive VP, CFO & COO | Mar 14, 2022 | Buy | +250 | $3.98 | $995 | 500 |
| Donald Marvin Executive VP, CFO & COO | Mar 14, 2022 | Buy | +250 | $4.00 | $1.00K | 250 |
| Donald Marvin Executive VP, CFO & COO | Mar 14, 2022 | Buy | +250 | $4.20 | $1.05K | 1,500 |
| Donald Marvin Executive VP, CFO & COO | Mar 14, 2022 | Buy | +250 | $4.10 | $1.03K | 1,250 |
| Donald Marvin Executive VP, CFO & COO | Mar 14, 2022 | Buy | +250 | $3.90 | $975 | 1,000 |
| Neil Harris Cohen Director | Mar 14, 2022 | Buy | +2,000 | $4.20 | $8.40K | 6,409 |
| Neil Harris Cohen Director | Mar 14, 2022 | Buy | +2,000 | $4.30 | $8.60K | 8,409 |
| Neil Harris Cohen Director | Mar 14, 2022 | Buy | +2,000 | $4.56 | $9.12K | 10,409 |
| Dale R. Pfost Chief Executive Officer, Director | Mar 14, 2022 | Buy | +1,800 | $3.98 | $7.16K | 1,800 |
| Dale R. Pfost Chief Executive Officer, Director | Mar 14, 2022 | Buy | +700 | $3.97 | $2.78K | 2,500 |
| Nissim Darvish Director | Mar 11, 2022 | Buy | +1,200 | $4.28 | $5.14K | 1,200 |
| Neil Harris Cohen Director | Dec 6, 2021 | Buy | +2,000 | $7.43 | $14.86K | 4,409 |
| Neil Harris Cohen Director | Mar 16, 2021 | Buy | +2,409 | $41.51 | $100.00K | 2,409 |
| Peter Thiel 10% owner | Mar 16, 2021 | Buy | +230,536 | – | – | 1,108,509 |
| Israel GP Ltd. OrbiMed 10% owner | Mar 16, 2021 | Award | +288,170 | $17.35 | $5.00M | 2,578,174 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Chemomab Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 14,542 shares on Aug 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| OrbiMed Israel Partners Limited Partnership Owner | Sep 12, 2024 | 500,000 | $1.02M | Sep 12, 2024 | Merger |
See a number that looks wrong?